The US is the leading destination market for greenfield pharmaceuticals FDI, while it is also the top source market. GlobalData’s pharmaceuticals foreign direct investment (FDI) report highlights the current trends in pharmaceuticals foreign investments. Buy the report here.
Between 2019 and 2022, the pharmaceuticals sector was the fifteenth largest FDI sector in terms of the number of greenfield investments. The pharmaceuticals sector accounts for 2% of global greenfield FDI projects.
Greenfield foreign direct investment is when a company invests abroad to establish a new physical presence or expand an existing operation. Greenfield investments create jobs and/or involve a capital investment into the foreign location. Other forms of FDI, such as mergers and acquisitions, are not included as part of this definition.
Combined, the top ten destination countries account for 58.3% of total pharmaceuticals FDI projects.
The leading destination country for pharmaceuticals FDI is the US. Germany, UK and France are also popular pharmaceuticals investment hubs.
According to GlobalData’s FDI Projects database, United Kingdom-based companies were the leading source of greenfield pharmaceuticals investments into the US.
With respect to outbound FDI, the US was the leading pharmaceuticals source market. US-based companies held a 26.3% share of total outbound pharmaceuticals FDI projects. Germany, UK, Switzerland and Japan are also top source markets for pharmaceuticals FDI.
To further understand global pharmaceuticals foreign direct investment trends, buy the report here.